<DOC>
	<DOCNO>NCT01080066</DOCNO>
	<brief_summary>This prospective , observational , non-interventional , multicenter , post-marketing surveillance study mainly collect safety information subject locally advanced recurrent/metastatic Squamous Cell Carcinoma Head Neck ( SCCHN ) treat cetuximab base locally approve label .</brief_summary>
	<brief_title>A Post Marketing Surveillance Study Cetuximab Patients With Squamous Cell Carcinoma Head Neck ( SCCHN )</brief_title>
	<detailed_description>Cetuximab immunoglobulin G1 ( IgG1 ) monoclonal antibody enhance effect common chemotherapy agent radiotherapy demonstrate minimal overlap toxicity approach . This prospective , observational , non-interventional multi-centric post marketing surveillance study conduct collect safety information subject locally advanced recurrent/metastatic SCCHN treat cetuximab base locally approve label . Study plan enroll 200 300 subject , eligible cetuximab treatment accord indication approve label cetuximab Taiwan Health Authority . Data related subject ' demographic , relevant tumor history , laboratory information ( hematology , biochemistry ) capture analyze descriptively . OBJECTIVES Primary objective : • To obtain safety information use cetuximab subject SCCHN accord regulatory approve label regular clinical setting Secondary objective : • To gather clinical efficacy information treatment</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically proven Stage 34 locally advanced SCCHN ( oropharynx , hypopharynx , larynx ) recurrent and/or metastatic SCCHN Age great equal 18 year Signed informed consent Subjects know severe ( Grade 3 4 ; National Cancer Institute Common Toxicity Criteria Version 4.03 ) hypersensitivity reaction Cetuximab Subjects contraindication concomitantly use chemotherapeutic agent radiation therapy , identify initiation cetuximab combination treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Squamous cell</keyword>
	<keyword>Erbitux</keyword>
	<keyword>cetuximab</keyword>
	<keyword>Head</keyword>
	<keyword>Neck</keyword>
</DOC>